文献速递膀胱癌与上尿路尿路上皮癌

非肌层浸润性膀胱癌5年无复发生存后的长期结局

Long-term outcomes following a 5-year recurrence-free interval in non-muscle-invasive bladder cancer.
PubMed 文献 · BJU Int · 2026-03-28

1年和5年复发累积发生率分别为24%和44%,进展风险分别为4.4%和10%。6583例5年无复发生存患者后续5年复发和进展累积发生率分别为9.8%和1.5%,其中三分之一进展为肌层浸润性膀胱癌。

要点

  • NMIBC的1年和5年复发累积发生率分别为24%和44%,进展风险分别为4.4%和10%。
  • 5年无复发生存后,后续5年复发和进展累积发生率分别为9.8%和1.5%。
  • 5年无复发生存后仍存在复发和进展风险,但仅限少数患者,其中三分之一进展为肌层浸润性膀胱癌。

核心结论

  • 大多数NMIBC复发发生在初诊后前几年,过去14年无复发生存率有所改善。
  • 5年无复发生存后复发和进展风险持续存在,但仅见于有限比例患者。

研究设计与样本

  • 复发定义为经尿道膀胱肿瘤切除术后≥90天出现新膀胱肿瘤,进展采用Lamm等标准或膀胱切除术。
  • 采用累积发生率和Cox回归分析初诊后5年内复发与进展风险,并对无复发生存≥5年者进行landmark分析评估晚期复发。

主要发现

  • 1年和5年复发累积发生率分别为24%(95%CI 24-25%)和44%(95%CI 43-45%)。
  • 1年和5年进展风险分别为4.4%(95%CI 4.1-4.7%)和10%(95%CI 9.7-11%)。
  • 6583例5年无复发生存患者后续5年复发累积发生率为9.8%(95%CI 9.0-11%),进展为1.5%(95%CI 1.2-1.9%)。
  • 5年无复发生存后发生进展的患者中,三分之一进展为肌层浸润性膀胱癌。

临床怎么用

  • NMIBC随访应重点关注初诊后前几年的高复发风险。
  • 5年无复发生存后仍需警惕晚期复发和进展,但风险较低,可考虑个体化长期随访方案。

局限性

  • 未来需研究识别可预测长期风险的具体危险因素,以定制NMIBC患者的长期随访方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe the recurrence and progression trends of non-muscle-invasive bladder cancer (NMIBC) during a 14-year period in Denmark between 2009 and 2022. Furthermore, to evaluate the risk of late recurrence with or without progression in patients who initially experience a 5-year recurrence-free interval (RFI). PATIENTS AND METHODS: We conducted a nationwide cohort study of all patients diagnosed with NMIBC in Denmark between 2009 and 2022, linking data from population-based registries (N = 21 037). Recurrence was defined as a new bladder tumour ≥90 days after transurethral resection of bladder tumour, and progression followed the criteria set out by Lamm et al. or cystectomy. Cumulative incidence and Cox regression analyses described risks of recurrence and progression within 5 years after primary diagnosis. A landmark analysis assessed late recurrences with or without progression among patients who were recurrence-free for ≥5 years. RESULTS: We identified 21 037 patients with NMIBC (median age 72 years; 76% male). The 1- and 5-year cumulative incidence of recurrence was 24% (95% confidence interval [CI] 24-25%) and 44% (95% CI 43-45%), while progression risks were 4.4% (95% CI 4.1-4.7%) and 10% (95% CI 9.7-11%). Among the 6583 patients who were recurrence-free for 5 years, the subsequent 5-year cumulative incidence was 9.8% (95% CI 9.0-11%) for recurrence and 1.5% (95% CI 1.2-1.9%) for progression, with one-third progressing to MIBC. CONCLUSION: Our study confirmed previous findings that most recurrences in patients with NMIBC occur within the first years after primary diagnosis. Furthermore, we found improved recurrence-free rates over the past 14 years. Our analysis suggests the risk of recurrence and progression persists after a 5-year RFI; however, only in a limited proportion of patients. Future studies should identify specific risk factors able to predict patients' long-term risk, to tailor potential long-term follow-up schemes for patients with NMIBC.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Hjort PB, Jensen JB, Ernst A, et al. Long-term outcomes following a 5-year recurrence-free interval in non-muscle-invasive bladder cancer. BJU Int. 2026. PMID: 41902493. doi:10.1111/bju.70267

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。